Cochrane Review Group

Hepato-Biliary

132 systematic reviews in Hepato-Biliary ask 1,521 questions. 19.9% have no studies to answer them, 57.6% rest on very low certainty evidence and 5.7% reach moderate or high certainty.

Reviews

132

Questions

1,521

current versions

No studies

19.9%

Moderate or high

5.7%

No studies 303 · 19.9%Ungraded 39 · 2.6%Very low 876 · 57.6%Low 216 · 14.2%Moderate 65 · 4.3%High 22 · 1.4%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Hepato-Biliary

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Microwave coagulation in addition to conventional transarterial chemoembolisation vs conventional transarterial chemoembolisation alone All‐cause mortality · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	no estimate extracted	NR	No studies
Microwave coagulation vs conventional surgery Health‐related quality of life · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	no estimate extracted	NR	No studies
Microwave coagulation vs conventional surgery Any adverse events or complications · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	no estimate extracted	1 study · 30 participants	Very low
Microwave coagulation vs conventional surgery Disease‐free survival · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	no estimate extracted	1 study · 30 participants	Very low
Microwave coagulation vs conventional surgery Failure to clear liver metastases · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	no estimate extracted	NR	No studies
Microwave coagulation vs conventional surgery Recurrence of liver metastases · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	no estimate extracted	NR	No studies
Microwave coagulation vs radiofrequency ablation All‐cause mortality · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	RR 0.62 [0.26, 1.47]	1 study · 50 participants	Very low
Microwave coagulation vs radiofrequency ablation Time to mortality (overall survival) · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	HR 0.63 [0.23, 1.73]	1 study · 50 participants	Very low
Microwave coagulation vs radiofrequency ablation Health‐related quality of life · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	no estimate extracted	NR	No studies
Microwave coagulation vs radiofrequency ablation Any adverse events or complications · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	RR 0.19 [0.01, 3.67]	1 study · 50 participants	Very low
Microwave coagulation vs radiofrequency ablation Disease‐free survival · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	no estimate extracted	NR	No studies
Microwave coagulation in addition to conventional transarterial chemoembolisation vs conventional transarterial chemoembolisation alone Time to mortality · people with liver metastases Microwave coagulation for liver metastases (2024) · Cochrane	no estimate extracted	NR	No studies

Reviews 132

Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta‐analysis

Iogna Prat, L, Wilson, P, et al. · Cochrane Database of Systematic Reviews · 2019

Hepato-Biliary

Thinnest evidence

Reviews 132

Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta‐analysis

Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haemorrhage in people with cirrhosis

Interventions for paracetamol (acetaminophen) overdose

Glucocorticosteroid‐free versus glucocorticosteroid‐containing immunosuppression for liver transplanted patients

Glucocorticosteroids for infants with biliary atresia following Kasai portoenterostomy

Laparoscopic‐endoscopic rendezvous versus preoperative endoscopic sphincterotomy in people undergoing laparoscopic cholecystectomy for stones in the gallbladder and bile duct

Carvedilol versus traditional, non‐selective beta‐blockers for adults with cirrhosis and gastroesophageal varices

Pharmacological interventions for acute hepatitis C infection

Surgical portosystemic shunts versus devascularisation procedures for prevention of variceal rebleeding in people with hepatosplenic schistosomiasis

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas

L‐ornithine L‐aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis

Physical exercise for people with cirrhosis

Branched‐chain amino acids for people with hepatic encephalopathy

Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy

Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome

Hepatitis B immunoglobulin during pregnancy for prevention of mother‐to‐child transmission of hepatitis B virus

Probiotics for people with hepatic encephalopathy

External beam radiotherapy for unresectable hepatocellular carcinoma

Pharmacological interventions for primary sclerosing cholangitis

Terlipressin versus other vasoactive drugs for hepatorenal syndrome

Nutrition support in hospitalised adults at nutritional risk

Maintenance immunosuppression for adults undergoing liver transplantation: a network meta‐analysis

Pharmacological interventions for non‐alcohol related fatty liver disease (NAFLD)

Pharmacological interventions for acute hepatitis B infection

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease)